On this week’s episode, we chat with Hans Eriksson, chief medical officer (CMO) of HMNC Brain Health, about ketamine and treatment-resistant depression, and with Krishna Polu, CEO, president and co-founder of new kidney health biotech company R1 Therapeutics.

Times:

03:57 HMNC Brain Health

29:47 R1 Therapeutics

HMNC Brain Health

HMNC Brain Health is a Munich-based clinical-stage biopharma company developing personalised treatments for depression. It has a phase 2 programme using oral, non-dissociative ketamine to treat treatment-resistant depression (TRD).

The Ketabon programme, a joint venture between HMNC Brain Health and Develco Pharma, features an oral prolonged-release formulation of ketamine (KET01) fo ...